1WC7 | pdb_00001wc7

FAB FRAGMENT OF PLP-DEPENDENT CATALYTIC ANTIBODY 15A9 IN COMPLEX WITH PHOSPHOPYRIDOXYL-L-ALANINE


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.33 Å
  • R-Value Free: 
    0.309 (Depositor) 
  • R-Value Work: 
    0.212 (DCC) 
  • R-Value Observed: 
    0.222 (Depositor) 

Starting Model: other
View more details

wwPDB Validation 3D Report Full Report

Validation slider image for 1WC7

Ligand Structure Quality Assessment 


This is version 1.6 of the entry. See complete history

Literature

Structure of a Pseudomerohedrally Twinned Monoclinic Crystal Form of a Pyridoxal Phosphate-Dependent Catalytic Antibody

Golinelli-Pimpaneau, B.

(2005) Acta Crystallogr D Biol Crystallogr 61: 472

  • DOI: https://doi.org/10.1107/S0907444905003331
  • Primary Citation Related Structures: 
    1WC7

  • PubMed Abstract: 

    The purification, crystallization and structure determination at 2.3 A resolution of the complex of the pyridoxal-5'-phosphate (PLP) dependent catalytic antibody 15A9 with a phosphopyridoxyl-L-alanine (PPL-L-alanine) substrate analogue are described. The crystal belongs to space group P2(1), with two molecules in the asymmetric unit related by non-crystallographic symmetry. The unit-cell parameters are a = 63.5, b = 81.7, c = 79.3 A and beta is fortuitously 90 degrees . Refinement of the structure converged at unacceptably high R factors. Although the traditional analysis of intensity distribution did not indicate twinning, pseudomerohedral twinning was revealed by a newer test based on local intensity differences [Padilla & Yeates (2003), Acta Cryst. D59, 1124-1130]. When the potential twinning operator was included in SHELX, the structure could be satisfactorily refined with a twinning fraction of 0.46, indicating a nearly perfect hemihedrally twinned crystal. One of the active sites is occupied by the phosphopyridoxyl-L-alanine ligand, while one iodide ion mimics the cofactor phosphate group in the other. Four other iodide ions are present in the structure: two are involved in specific intermolecular contacts and two dictate the conformation of the CDRH3 loop in each molecule.


  • Organizational Affiliation
    • Laboratoire d'Enzymologie et de Biochimie Structurales, Bâtiment 34, CNRS, 1 Avenue de la Terrasse, 91190 Gif-sur-Yvette, France. beatrice.golinelli@lebs.cnrs-gif.fr

Macromolecule Content 

  • Total Structure Weight: 96.67 kDa 
  • Atom Count: 6,610 
  • Modeled Residue Count: 873 
  • Deposited Residue Count: 878 
  • Unique protein chains: 2

Macromolecules

Find similar proteins by:|  3D Structure
Entity ID: 1
MoleculeChains  Sequence LengthOrganismDetailsImage
FAB FRAGMENT OF CATALYTIC ANTIBODY 15A9, LIGHT CHAINA,
D [auth L]
213Mus musculusMutation(s): 0 
Find similar proteins by:|  3D Structure
Entity ID: 2
MoleculeChains  Sequence LengthOrganismDetailsImage
FAB FRAGMENT OF CATALYTIC ANTIBODY 15A9, HEAVY CHAINB,
C [auth H]
226Mus musculusMutation(s): 0 

Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.33 Å
  • R-Value Free:  0.309 (Depositor) 
  • R-Value Work:  0.212 (DCC) 
  • R-Value Observed: 0.222 (Depositor) 
Space Group: P 1 21 1
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 63.476α = 90
b = 81.691β = 89.98
c = 79.33γ = 90
Software Package:
Software NamePurpose
SHELXL-97refinement
DENZOdata reduction
SCALEPACKdata scaling
AMoREphasing

Structure Validation

View Full Validation Report



Ligand Structure Quality Assessment 


Entry History 

Deposition Data

Revision History  (Full details and data files)

  • Version 1.0: 2005-11-30
    Type: Initial release
  • Version 1.1: 2011-05-08
    Changes: Version format compliance
  • Version 1.2: 2011-07-13
    Changes: Version format compliance
  • Version 1.3: 2019-01-30
    Changes: Data collection, Experimental preparation, Other
  • Version 1.4: 2019-05-22
    Changes: Data collection, Refinement description
  • Version 1.5: 2024-05-01
    Changes: Data collection, Database references, Other, Refinement description
  • Version 1.6: 2024-11-13
    Changes: Structure summary